

Vivek Gupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4128424/publications.pdf>

Version: 2024-02-01

74
papers

4,000
citations

109137

35
h-index

118652

62
g-index

74
all docs

74
docs citations

74
times ranked

5949
citing authors

#	ARTICLE	IF	CITATIONS
1	Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10753-10758.	3.3	554
2	Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen through Adsorption on Red Blood Cells. ACS Nano, 2013, 7, 11129-11137.	7.3	276
3	Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discovery Today, 2019, 24, 2076-2085.	3.2	239
4	Microfluidics-based 3D cell culture models: Utility in novel drug discovery and delivery research. Bioengineering and Translational Medicine, 2016, 1, 63-81.	3.9	167
5	Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nature Nanotechnology, 2017, 12, 589-594.	15.6	154
6	Monocyte-mediated delivery of polymeric backpacks to inflamed tissues: a generalized strategy to deliver drugs to treat inflammation. Journal of Controlled Release, 2015, 199, 29-36.	4.8	130
7	PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. Journal of Controlled Release, 2012, 162, 310-320.	4.8	124
8	In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. European Journal of Pharmaceutical Sciences, 2013, 49, 805-818.	1.9	121
9	Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. Journal of Controlled Release, 2013, 167, 189-199.	4.8	105
10	Topical delivery of hyaluronic acid into skin using SPACE-peptide carriers. Journal of Controlled Release, 2014, 173, 67-74.	4.8	100
11	Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. International Journal of Biological Macromolecules, 2019, 122, 338-347.	3.6	95
12	Topical delivery of siRNA into skin using SPACE-peptide carriers. Journal of Controlled Release, 2014, 179, 33-41.	4.8	91
13	The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells. PLoS ONE, 2016, 11, e0152074.	1.1	90
14	Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges. Life Sciences, 2020, 259, 118275.	2.0	89
15	Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: Synergy between physical, chemical and biological approaches. Biomaterials, 2015, 68, 1-8.	5.7	76
16	Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. International Journal of Pharmaceutics, 2009, 379, 41-50.	2.6	74
17	Particle Size Influences the Immune Response Produced by Hepatitis B Vaccine Formulated in Inhalable Particles. Pharmaceutical Research, 2010, 27, 905-919.	1.7	72
18	Mucoadhesive intestinal devices for oral delivery of salmon calcitonin. Journal of Controlled Release, 2013, 172, 753-762.	4.8	69

#	ARTICLE	IF	CITATIONS
19	A permeation enhancer for increasing transport of therapeutic macromolecules across the intestine. <i>Journal of Controlled Release</i> , 2013, 172, 541-549.	4.8	64
20	Inhalable resveratrol-cyclodextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer. <i>International Journal of Biological Macromolecules</i> , 2020, 164, 638-650.	3.6	60
21	Role of In Vitro Release Methods in Liposomal Formulation Development: Challenges and Regulatory Perspective. <i>AAPS Journal</i> , 2017, 19, 1669-1681.	2.2	57
22	Metformin-Encapsulated Liposome Delivery System: An Effective Treatment Approach against Breast Cancer. <i>Pharmaceutics</i> , 2019, 11, 559.	2.0	53
23	Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment. <i>Pharmaceutics</i> , 2020, 12, 206.	2.0	53
24	Development of inhalable quinacrine loaded bovine serum albumin modified cationic nanoparticles: Repurposing quinacrine for lung cancer therapeutics. <i>International Journal of Pharmaceutics</i> , 2020, 577, 118995.	2.6	53
25	PLGA Microparticles Encapsulating Prostaglandin E1-Hydroxypropyl- β -cyclodextrin (PGE1-HP β CD) Complex for the Treatment of Pulmonary Arterial Hypertension (PAH). <i>Pharmaceutical Research</i> , 2011, 28, 1733-1749.	1.7	48
26	Influence of PEI as a core modifying agent on PLGA microspheres of PGE1, a pulmonary selective vasodilator. <i>International Journal of Pharmaceutics</i> , 2011, 413, 51-62.	2.6	48
27	Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability. <i>Carbohydrate Polymers</i> , 2019, 204, 68-77.	5.1	47
28	Delivery of Exenatide and Insulin Using Mucoadhesive Intestinal Devices. <i>Annals of Biomedical Engineering</i> , 2016, 44, 1993-2007.	1.3	44
29	Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 133, 145-159.	1.9	44
30	Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7575.	1.8	44
31	Permeation of Insulin, Calcitonin and Exenatide across Caco-2 Monolayers: Measurement Using a Rapid, 3-Day System. <i>PLoS ONE</i> , 2013, 8, e57136.	1.1	42
32	Exploring potential of quantum dots as dual modality for cancer therapy and diagnosis. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 49, 352-364.	1.4	41
33	Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer. <i>Pharmaceutical Research</i> , 2020, 37, 67.	1.7	40
34	Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. <i>Scientific Reports</i> , 2015, 5, 13476.	1.6	38
35	Enhanced solubility, stability, permeation and anti-cancer efficacy of Celastrol- β -cyclodextrin inclusion complex. <i>Journal of Molecular Liquids</i> , 2020, 318, 113936.	2.3	38
36	Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 38, 165-171.	1.9	37

#	ARTICLE	IF	CITATIONS
37	Topical delivery of Cyclosporine A into the skin using SPACE-peptide. <i>Journal of Controlled Release</i> , 2015, 199, 190-197.	4.8	37
38	Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery. <i>Journal of Controlled Release</i> , 2015, 211, 118-133.	4.8	36
39	Exosomes: Natural Carriers for siRNA Delivery. <i>Current Pharmaceutical Design</i> , 2015, 21, 4556-4565.	0.9	35
40	Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC) – development and in-vitro efficacy. <i>Drug Delivery and Translational Research</i> , 2021, 11, 927-943.	3.0	34
41	Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. <i>Journal of Pharmaceutical Sciences</i> , 2010, 99, 1774-1789.	1.6	29
42	Development of pharmaceutically scalable inhaled anti-cancer nanotherapy – Repurposing amodiaquine for non-small cell lung cancer (NSCLC). <i>Materials Science and Engineering C</i> , 2020, 115, 111139.	3.8	28
43	Metformin-loaded chitosomes for treatment of malignant pleural mesothelioma – A rare thoracic cancer. <i>International Journal of Biological Macromolecules</i> , 2020, 160, 128-141.	3.6	27
44	Cyclodextrin Complexation for Enhanced Stability and Non-invasive Pulmonary Delivery of Resveratrol – Applications in Non-small Cell Lung Cancer Treatment. <i>AAPS PharmSciTech</i> , 2020, 21, 183.	1.5	26
45	Inhalable Lactose-Based Dry Powder Formulations of Low Molecular Weight Heparin. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, 97-104.	0.7	25
46	Inhaled PLGA Particles of Prostaglandin E ₁ Ameliorate Symptoms and Progression of Pulmonary Hypertension at a Reduced Dosing Frequency. <i>Molecular Pharmaceutics</i> , 2013, 10, 1655-1667.	2.3	25
47	Inhalational Therapy for Pulmonary Arterial Hypertension: Current Status and Future Prospects. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2010, 27, 313-370.	1.2	24
48	Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4783.	1.8	20
49	Computational and bioengineered lungs as alternatives to whole animal, isolated organ, and cell-based lung models. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012, 303, L733-L747.	1.3	18
50	The preparation of lipid-based drug delivery system using melt extrusion. <i>Drug Discovery Today</i> , 2020, 25, 1930-1943.	3.2	15
51	Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation. <i>Drug Delivery and Translational Research</i> , 2022, 12, 2474-2487.	3.0	15
52	Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). <i>Pharmaceutical Research</i> , 2020, 37, 123.	1.7	14
53	Advances in treatment of pulmonary arterial hypertension: patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 907-918.	2.4	13
54	Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6306.	1.8	12

#	ARTICLE	IF	CITATIONS
55	Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation â€ Evaluation of intestinal absorption and anti-cancer activity. Journal of Molecular Liquids, 2021, 327, 114866.	2.3	12
56	Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics â€ Evaluation in biologically relevant in-vitro models. Materials Science and Engineering C, 2021, 121, 111891.	3.8	9
57	Statistical optimization and validation of a novel ultra-performance liquid chromatography method for estimation of nintedanib in rat and human plasma. Bioanalysis, 2020, 12, 159-174.	0.6	8
58	Development and characterization of inhalable transferrin functionalized amodiaquine nanoparticles â€ Efficacy in Non-Small Cell Lung Cancer (NSCLC) treatment. International Journal of Pharmaceutics, 2021, 608, 121038.	2.6	8
59	Optimizing the aryl-triazole of cjoc42 for enhanced gankyrin binding and anti-cancer activity. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127372.	1.0	7
60	Bioinspired particle engineering for non-invasive inhaled drug delivery to the lungs. Materials Science and Engineering C, 2021, 128, 112324.	3.8	7
61	Therapeutic potential of inhalable medications to combat coronavirus disease-2019. Therapeutic Delivery, 2021, 12, 105-110.	1.2	6
62	Exploitation of Novel Molecular Targets to Treat Idiopathic Pulmonary Fibrosis: A Drug Discovery Perspective. Current Medicinal Chemistry, 2017, 24, 2439-2458.	1.2	6
63	Particle shape engineering for improving safety and efficacy of doxorubicin â€ A case study of rod-shaped carriers in resistant small cell lung cancer. , 2022, 137, 212850.		6
64	Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer. Journal of Medicinal Chemistry, 2022, 65, 8975-8997.	2.9	6
65	Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective. Therapeutic Delivery, 2020, 11, 213-215.	1.2	5
66	Bioadhesive Polymers for Targeted Drug Delivery. , 2017, , 322-362.		4
67	Repurposing therapeutics for malignant pleural mesothelioma (MPM) â€ Updates on clinical translations and future outlook. Life Sciences, 2022, 304, 120716.	2.0	3
68	Editorial (Thematic Issue: Novel Therapeutic Strategies for Cardiovascular Disease Treatment: From) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	1
69	Analytical challenges and advancements in bioanalysis of therapeutic proteins. Bioanalysis, 2020, 12, 207-209.	0.6	1
70	Principles and Practice of Pulmonary Drug Delivery. , 2010, , 371-419.		1
71	Multiple Pathway Modulating Therapy for Pulmonary Hypertension: A Survey of Practice Patterns and Perceptions. Chest, 2016, 150, 1186A.	0.4	0
72	Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	Emerging Therapeutic Targets and Therapies in Idiopathic Pulmonary Fibrosis. Molecular and Translational Medicine, 2019, , 197-237.	0.4	0
74	Current Status and Perspectives in Mucosal Drug Delivery of Nanotherapeutic Systems. AAPS Advances in the Pharmaceutical Sciences Series, 2020, , 83-106.	0.2	0